Table 7.
Logistic regression analysis for developing advanced liver fibrosis
| OR | 95% CI | p | ||
|---|---|---|---|---|
| Lower | Upper | |||
| Age [younger age group (ref.)] | 2.908 | 2.597 | 3.256 | <0.001 |
| Sex [male (ref.)] | 0.998 | 0.891 | 1.118 | 0.972 |
| NAFLD (ref.) | ||||
| HCV | 2.582 | 2.168 | 3.075 | <0.001 |
| HBV | 0.800 | 0.702 | 0.911 | <0.001 |
| Metabolic liver diseases | 1.893 | 0.912 | 3.928 | 0.087 |
| DILI | 0.955 | 0.630 | 1.447 | 0.826 |
| Cholestatic liver diseases | 1.392 | 0.840 | 2.307 | 0.200 |
| ALD | 2.019 | 1.524 | 2.674 | <0.001 |
| AIH | 2.138 | 1.360 | 3.660 | <0.001 |
Variables included in the model: advanced fibrosis, gender, age, and CLD etiology. OR: Odds ratio; CI: Confidence interval; NAFLD: Nonalcoholic fatty liver disease; HCV: Hepatitis C virus; HBV: Hepatitis B virus; DILI: Drug-induced liver injury; PSC/PBC: Primary sclerosing cholangitis and primary biliary cirrhosis; ALD: Alcoholic liver disease; AIH: Autoimmune hepatitis.